title: Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
abstract: Attenuation of increased endocannabinoid signaling with a CB1R neutral antagonist might offer a new therapeutic direction for treatment of alcohol abuse. We have recently reported that a monohydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits neutral antagonist activity at CB1Rs and thus may serve as a promising lead for the development of novel alcohol abuse therapies. In the current study, we show that systematic modification of an aminoalkylindole scaffold identified two new compounds with dual CB1R antagonist/CB2R agonist activity. Similar to the CB1R antagonist/inverse agonist rimonabant, analogues 27 and 30 decrease oral alcohol self-administration without affecting total fluid intake and block the development of alcohol-conditioned place preference. Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.
authors: Department of Medicinal Chemistry, School of Pharmacy, The University of Kansas, Lawrence, Kansas 66045, USA.
authors: Tamara
authors: T
authors: Vasiljevik
authors: Lirit N
authors: LN
authors: Franks
authors: Benjamin M
authors: BM
authors: Ford
authors: Justin T
authors: JT
authors: Douglas
authors: Paul L
authors: PL
authors: Prather
authors: William E
authors: WE
authors: Fantegrossi
authors: Thomas E
authors: TE
authors: Prisinzano
mesh_terms: D000437:Alcoholism / Q000188:drug therapy*; D000818:Animals; D016466:CHO Cells; D063386:Cannabinoid Receptor Agonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D063387:Cannabinoid Receptor Antagonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D003214:Conditioning, Classical / Q000187:drug effects; D006224:Cricetinae; D003412:Cricetulus; D015195:Drug Design; D054314:Drug Inverse Agonism; D000431:Ethanol / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D008024:Ligands; D051379:Mice; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists; D043882:Receptors, Cannabinoid / Q000378:metabolism*; D012646:Self Administration; D013329:Structure-Activity Relationship
chemical_list: D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D007211:Indoles; D008024:Ligands; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D000431:Ethanol
references: Bioorg Med Chem. 2005 Jan 3;13(1):89-112
references: 15582455
references: Lancet. 2007 Nov 17;370(9600):1706-13
references: 18022033
references: Neuropsychiatr Dis Treat. 2007 Dec;3(6):711-21
references: 19300605
references: J Neurochem. 2003 Feb;84(4):698-704
references: 12562514
references: Biochem Pharmacol. 2012 Apr 1;83(7):952-61
references: 22266354
references: J Pharmacol Exp Ther. 2005 Aug;314(2):868-75
references: 15901805
references: Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53
references: 12399252
references: Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R343-4
references: 12529283
references: Expert Opin Emerg Drugs. 2012 Mar;17(1):17-29
references: 22335400
references: Neuropsychopharmacology. 2008 Mar;33(4):946-55
references: 17581535
references: J Pharmacol Exp Ther. 1998 Jun;285(3):995-1004
references: 9618400
references: Alcohol Res Health. 2000;24(2):85-92
references: 11199282
references: J Pharmacol Exp Ther. 1992 Jan;260(1):201-9
references: 1309872
references: Mol Interv. 2011 Feb;11(1):36-51
references: 21441120
references: Drug Alcohol Depend. 2000 Aug 1;60(2):133-40
references: 10940540
references: Lancet. 2009 Jun 27;373(9682):2223-33
references: 19560604
references: Nat Med. 2012 Apr 05;18(4):504-5
references: 22481411
references: Alcohol Alcohol. 1989;24(4):299-309
references: 2675861
references: Mini Rev Med Chem. 2007 Aug;7(8):769-79
references: 17692039
references: J Org Chem. 2008 Jun 20;73(12):4638-43
references: 18494524
references: Pharmacol Ther. 2006 Sep;111(3):855-76
references: 16545872
references: Nat Neurosci. 2011 Jul 24;14(9):1160-6
references: 21785434
references: Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65
references: 19249987
references: J Neurochem. 1999 Feb;72(2):522-8
references: 9930723
references: Brain Res. 1998 May 18;793(1-2):212-8
references: 9630633
references: Crit Rev Neurobiol. 1998;12(4):339-69
references: 10348615
references: Mol Pharmacol. 2000 May;57(5):1000-10
references: 10779385
references: Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8
references: 12538878
references: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references: 4202581
references: CNS Neurol Disord Drug Targets. 2010 Mar;9(1):55-9
references: 20201816
references: Curr Top Behav Neurosci. 2009;1:309-46
references: 21104390
references: J Med Chem. 2011 Mar 10;54(5):1356-64
references: 21280601
references: Synapse. 2008 Aug;62(8):574-81
references: 18509854
references: J Med Toxicol. 2012 Mar;8(1):15-32
references: 22271566
references: Pharmacol Rep. 2010 Sep-Oct;62(5):797-807
references: 21098863
references: Behav Pharmacol. 2012 Sep;23(5-6):537-50
references: 22743603
references: Addict Biol. 2007 Sep;12(3-4):227-462
references: 17678505
references: Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
references: 1666911
references: Lancet. 2005 Apr 16-22;365(9468):1389-97
references: 15836887